Clinical trialNCT03969420TerminatedPhase 2Interventional

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

SponsorSumitomo Pharma America, Inc.Enrollment11Acute Myeloid Leukemia (AML)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Stephen Anthony, DO
Sumitomo Pharma America, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Community Medical Providers
Clovis, California, United States
City of Hope National Medical Center, City of Hope Medical Center
Duarte, California, United States
Ronald Reagan Ucla Medical Center
Los Angeles, California, United States
University of California, San Francisco Medical Center
San Francisco, California, United States
Advent Health Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida, United States
Orlando Health, Inc, Univ of Florida Health Cancer Center
Orlando, Florida, United States
Indiana Blood and Marrow Translplantation - Clinic
Indianapolis, Indiana, United States
University of Kansas Medical Center
Westwood, Kansas, United States
Ochsner Medical Center
New Orleans, Louisiana, United States
University of New Mexico
Albuquerque, New Mexico, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Columbia University Medical Center
New York, New York, United States
University of North Carolina (unc)
Chapel Hill, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Oregon Health & Sciences University - Knight Cancer Institute - Center for Hematologic Malignancies
Portland, Oregon, United States
Allegheny Health Network
Pittsburgh, Pennsylvania, United States
Baylor University Center
Dallas, Texas, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Alvocidib →Alvocidib and cytarabine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jan 2020
Primary completion: 22 Apr 2021
Completion: 14 May 2021
Last update posted: 9 Nov 2023
Registered enrollment: 11
Registry id: NCT03969420

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.